サレプタ・セラピューティックス - 関連ニュース

OtherMarketBeat

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic

yesterday

OtherPRNewsWire

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK CITY and NEW ORLEANS, Sept. 4, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

12 days ago

NewsSeeking Alpha

Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

last month